OM:CAMXPharmaceuticals
How Investors Are Reacting To Camurus (OM:CAMX) Expanding Into Long‑Acting Hypoparathyroidism Treatments
Earlier this year, Camurus and Gubra announced an exclusive collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism, combining Gubra’s parathyroid hormone analogue with Camurus’ FluidCrystal drug delivery technology.
The deal adds a new endocrine indication to Camurus’ long-acting depot pipeline, potentially broadening its addressable market beyond current focus areas.
Next, we’ll examine how adding a long-acting hypoparathyroidism program may reshape...